Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Giovanni Citterio, Teresa Calimeri & Andrés J. M. Ferreri. (2018) Challenges and prospects in the diagnosis and treatment of primary central nervous system lymphoma. Expert Review of Neurotherapeutics 18:5, pages 379-393.
Read now
Read now
Saurabh Dahiya, Erin S Murphy, Samuel T Chao, Glen HJ Stevens, David M Peereboom & Manmeet S Ahluwalia. (2013) Recurrent or refractory primary central nervous lymphoma: therapeutic considerations. Expert Review of Anticancer Therapy 13:9, pages 1109-1119.
Read now
Read now
Lois A. Lampson. (2011) Monoclonal antibodies in neuro-oncology. mAbs 3:2, pages 153-160.
Read now
Read now
Kristoph Jahnke & Eckhard Thiel. (2009) Treatment options for central nervous system lymphomas in immunocompetent patients. Expert Review of Neurotherapeutics 9:10, pages 1497-1509.
Read now
Read now
Articles from other publishers (33)
Ryan J. Pakula & Peter J. H. Scott. (2023) Applications of radiolabeled antibodies in neuroscience and neuro‐oncology. Journal of Labelled Compounds and Radiopharmaceuticals 66:9, pages 269-285.
Crossref
Crossref
Wei Sun, Ruochen Liu, Xinyue Gao, Zini Lin, Hongao Tang, Hongjuan Cui & Erhu Zhao. (2023) Targeting serine-glycine-one-carbon metabolism as a vulnerability in cancers. Biomarker Research 11:1.
Crossref
Crossref
Kaiyan Tao, Xuefeng Wang & Xin Tian. (2021) Relapsed Primary Central Nervous System Lymphoma: Current Advances. Frontiers in Oncology 11.
Crossref
Crossref
Xaver U Kahle, Filipe M Montes de Jesus, Andor W J M Glaudemans, Marjolijn N Lub-de Hooge, Annelies Jorritsma-Smit, Wouter J Plattel, Tom van Meerten, Arjan Diepstra, Anke van den Berg, Thomas C Kwee, Walter Noordzij, Elisabeth G E de Vries & Marcel Nijland. (2020) Molecular imaging in lymphoma beyond 18F-FDG-PET: understanding the biology and its implications for diagnostics and therapy. The Lancet Haematology 7:6, pages e479-e489.
Crossref
Crossref
Louis Royer-Perron & Khê Hoang-Xuan. (2018) Management of primary central nervous system lymphoma. La Presse Médicale 47:11-12, pages e213-e244.
Crossref
Crossref
Giovanni Citterio, Michele Reni, Gemma Gatta & Andrés José Maria Ferreri. (2017) Primary central nervous system lymphoma. Critical Reviews in Oncology/Hematology 113, pages 97-110.
Crossref
Crossref
Liren QianCiprian TomuleasaIoan-Alexandru FlorianJianliang ShenIoan-Stefan FlorianMihnea ZdrengheaDelia Dima. (2017) Advances in the treatment of newly diagnosed primary central nervous system lymphomas. Blood Research 52:3, pages 159.
Crossref
Crossref
Hanne Kuitunen, Susanna Tokola, Topi Siniluoto, Matti Isokangas, Eila Sonkaj?rvi, Seppo Alahuhta, Taina Turpeenniemi-Hujanen, Esa Jantunen, Tapio Nousiainen, Kaija Vasala & Outi Kuittinen. (2016) Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL). Journal of Neuro-Oncology 131:2, pages 293-300.
Crossref
Crossref
Galen Leung, Marianna Papademetriou, Shannon Chang, Francis Arena & Seymour Katz. (2016) Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy. Current Treatment Options in Gastroenterology 14:4, pages 507-534.
Crossref
Crossref
Yi-Bin Chen, Tracy Batchelor, Shuli Li, Ephraim Hochberg, Mark Brezina, Sooae Jones, Candice Del Rio, Morgan Curtis, Karen K. Ballen, Jeffrey Barnes, Andrew S. Chi, Jorg Dietrich, Jessica Driscoll, Elizabeth R. Gertsner, Fred Hochberg, Ann S. LaCasce, Steven L. McAfee, Thomas R. Spitzer, Lakshmi Nayak & Philippe Armand. (2015) Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer 121:2, pages 226-233.
Crossref
Crossref
Bogdana Suchorska, Joerg C. Tonn & Nathalie L. Jansen. (2014) PET imaging for brain tumor diagnostics. Current Opinion in Neurology 27:6, pages 683-688.
Crossref
Crossref
Tali Siegal. (2014) Primary central nervous system lymphoma: Current state of anti-CD20 therapy and appraisal of reported response criteria. Journal of Clinical Neuroscience 21:5, pages 709-715.
Crossref
Crossref
M. Ponzoni, S. Issa, T.T. Batchelor & J.L. Rubenstein. (2014) Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma. Annals of Oncology 25:2, pages 316-322.
Crossref
Crossref
Nancy D. Doolittle, Leslie L. Muldoon, Aliana Y. Culp & Edward A. Neuwelt. 2014. Pharmacology of the Blood Brain Barrier: Targeting CNS Disorders. Pharmacology of the Blood Brain Barrier: Targeting CNS Disorders
203
243
.
Xiaoyin Jiang, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jennifer A. Quinn, Alan D. Austin, James E. Herndon2nd2nd, Roger E. McLendon & Henry S. Friedman. (2013) O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma. Journal of Neuro-Oncology 114:1, pages 135-140.
Crossref
Crossref
Tingzhong Wang, Forrest M. Kievit, Omid Veiseh, Hamed Arami, Zachary R. Stephen, Chen Fang, Yunhui Liu, Richard G. Ellenbogen & Miqin Zhang. (2013) Targeted Cell Uptake of a Noninternalizing Antibody Through Conjugation to Iron Oxide Nanoparticles in Primary Central Nervous System Lymphoma. World Neurosurgery 80:1-2, pages 134-141.
Crossref
Crossref
Anand K. Deo, Frank-Peter Theil & Jean-Marie Nicolas. (2013) Confounding Parameters in Preclinical Assessment of Blood–Brain Barrier Permeation: An Overview With Emphasis on Species Differences and Effect of Disease States. Molecular Pharmaceutics 10:5, pages 1581-1595.
Crossref
Crossref
Frank Lieberman, Victor Yazbeck, Anastasios Raptis, Raymond Felgar & Michael Boyiadzis. (2011) Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation. Journal of Neuro-Oncology 107:2, pages 225-232.
Crossref
Crossref
Camilo E. Fadul & Pamela Ely. 2012. Schmidek and Sweet Operative Neurosurgical Techniques. Schmidek and Sweet Operative Neurosurgical Techniques
149
159
.
David M. Goldenberg & Robert M. Sharkey. 2014. Therapeutic Nuclear Medicine. Therapeutic Nuclear Medicine
125
138
.
Leslie L. Muldoon, Seth J. Lewin, Edit Dósa, Dale F. Kraemer, Michael A. Pagel, Nancy D. Doolittle & Edward A. Neuwelt. (2011) Imaging and Therapy with Rituximab Anti-CD20 Immunotherapy in an Animal Model of Central Nervous System Lymphoma. Clinical Cancer Research 17:8, pages 2207-2215.
Crossref
Crossref
Robert M Sharkey & David M Goldenberg. (2011) Cancer radioimmunotherapy. Immunotherapy 3:3, pages 349-370.
Crossref
Crossref
Luis Solorio, Ravi B Patel, Hanping Wu, Tianyi Krupka & Agata A Exner. (2010) Advances in image-guided intratumoral drug delivery techniques. Therapeutic Delivery 1:2, pages 307-322.
Crossref
Crossref
Thomas E. Witzig. 2010. Monoclonal Antibody and Peptide‐Targeted Radiotherapy of Cancer. Monoclonal Antibody and Peptide‐Targeted Radiotherapy of Cancer
169
218
.
Umberto Vitolo, Giovanni Barosi, Stefano Fanti, Alessandro M. Gianni, Maurizio Martelli, Mario Petrini, Pier Luigi Zinzani & Sante Tura. (2010) Consensus conference on the use of 90‐yttrium‐ibritumomab tiuxetan therapy in clinical practice. A project of the Italian Society of Hematology. American Journal of Hematology 85:2, pages 147-155.
Crossref
Crossref
Kristoph Jahnke, Leslie L. Muldoon, Csanad G. Varallyay, Seth J. Lewin, Robert D. Brown, Dale F. Kraemer, Carole Soussain & Edward A. Neuwelt. (2009) Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma. Neuro-Oncology 11:5, pages 503-513.
Crossref
Crossref
Deborah T. Blumenthal. 2009. International Neurology. International Neurology
535
538
.
Sofiane Maza, Philipp Kiewe, Dieter L. Munz, Agnieszka Korfel, Bernd Hamm, Kristoph Jahnke & Eckhard Thiel. (2009) First report on a prospective trial with yttrium-90–labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. Neuro-Oncology 11:4, pages 423-429.
Crossref
Crossref
Lilyana AngelovNancy D. DoolittleDale F. KraemerTali SiegalGene H. BarnettDavid M. PeereboomGlen StevensJohn McGregorKristoph JahnkeCynthia A. LacyNancy A. HedrickEdna ShalomSandra FerenceSusan BellLisa SorensonRose Marie TysonMarianne HaluskaEdward A. Neuwelt. (2009) Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience. Journal of Clinical Oncology 27:21, pages 3503-3509.
Crossref
Crossref
Uwe Schlegel. (2009) Review: Primary CNS lymphoma. Therapeutic Advances in Neurological Disorders 2:2, pages 93-104.
Crossref
Crossref
U. Schlegel, A. Korfel, E. Thiel, W. Wick, R. Kortmann, M. Deckert & G. Schackert. (2009) Primäre ZNS-LymphomePrimary CNS lymphomas. Der Onkologe 15:3, pages 211-221.
Crossref
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:2, pages 115-122.
Crossref
Crossref
Edward Neuwelt, N Joan Abbott, Lauren Abrey, William A Banks, Brian Blakley, Thomas Davis, Britta Engelhardt, Paula Grammas, Maiken Nedergaard, John Nutt, William Pardridge, Gary A Rosenberg, Quentin Smith & Lester R Drewes. (2008) Strategies to advance translational research into brain barriers. The Lancet Neurology 7:1, pages 84-96.
Crossref
Crossref